TRCT
AMED

Tower Research Capital (TRC)’s Amedisys AMED Stock Holding History

Tower Research Capital (TRC)’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-669
Closed -$65.8K – 5205
2025
Q2 		$65.8K Sell
669
-376
-36% -$35.6K ﹤0.01% 2735
2025
Q1 		$96.8K Sell
1,045
-2,467
-70% -$227K ﹤0.01% 1795
2024
Q4 		$319K Buy
3,512
+1,396
+66% +$128K 0.01% 1360
2024
Q3 		$204K Sell
2,116
-8,287
-80% -$809K 0.01% 1605
2024
Q2 		$955K Buy
10,403
+4,617
+80% +$428K 0.02% 792
2024
Q1 		$533K Buy
5,786
+3,522
+156% +$330K 0.01% 831
2023
Q4 		$215K Buy
2,264
+127
+6% +$11.9K ﹤0.01% 2046
2023
Q3 		$200K Sell
2,137
-2,647
-55% -$245K 0.01% 1436
2023
Q2 		$437K Sell
4,784
-1,017
-18% -$83.4K 0.01% 1065
2023
Q1 		$426K Buy
5,801
+2,697
+87% +$233K 0.01% 929
2022
Q4 		$260K Sell
3,104
-4,737
-60% -$427K 0.01% 1122
2022
Q3 		$759K Hold
7,841
– – 0.01% 842
2022
Q2 		$825K Buy
7,841
+2,397
+44% +$306K 0.02% 818
2022
Q1 		$938K Buy
5,444
+3,210
+144% +$480K 0.01% 813
2021
Q4 		$361K Buy
2,234
+48
+2% +$7.71K 0.01% 1348
2021
Q3 		$326K Sell
2,186
-31
-1% -$6.44K 0.01% 1314
2021
Q2 		$543K Buy
2,217
+1,321
+147% +$347K 0.01% 1123
2021
Q1 		$237K Sell
896
-11,902
-93% -$3.36M ﹤0.01% 1872
2020
Q4 		$3.75M Sell
12,798
-2,585
-17% -$663K 0.11% 107
2020
Q3 		$3.64M Buy
15,383
+2,995
+24% +$681K 0.04% 137
2020
Q2 		$2.46M Buy
12,388
+12,382
+206,367% +$2.31M 0.1% 175
2020
Q1 		$1K Sell
6
-34
-85% -$6.05K ﹤0.01% 2720
2019
Q4 		$7K Sell
40
-496
-93% -$73.8K ﹤0.01% 2495
2019
Q3 		$70K Sell
536
-1,605
-75% -$209K ﹤0.01% 1555
2019
Q2 		$260K Buy
2,141
+2,134
+30,486% +$253K 0.02% 747
2019
Q1 		$1K Sell
7
-34
-83% -$4.27K ﹤0.01% 3521
2018
Q4 		$5K Buy
+41
New +$4.83K ﹤0.01% 2873
2018
Q2 		– Sell
-189
Closed -$11K – 3605
2018
Q1 		$11K Buy
+189
New +$10.8K ﹤0.01% 2418
2017
Q4 		– Sell
-2,436
Closed -$136K – 3470
2017
Q3 		$136K Buy
2,436
+2,336
+2,336% +$124K 0.01% 1074
2017
Q2 		$6K Buy
+100
New +$5.82K ﹤0.01% 1866
2017
Q1 		– Sell
-208
Closed -$9K – 3004
2016
Q4 		$9K Sell
208
-430
-67% -$18.3K ﹤0.01% 2705
2016
Q3 		$30K Buy
638
+527
+475% +$26.3K ﹤0.01% 1397
2016
Q2 		$6K Buy
+111
New +$5.6K ﹤0.01% 3240
2016
Q1 		– Sell
-666
Closed -$26K – 4058
2015
Q4 		$26K Buy
666
+572
+609% +$22.9K ﹤0.01% 1005
2015
Q3 		$4K Sell
94
-186
-66% -$7.84K ﹤0.01% 2896
2015
Q2 		$11K Sell
280
-1,464
-84% -$45.6K ﹤0.01% 2598
2015
Q1 		$46K Sell
1,744
-90
-5% -$2.54K 0.01% 1530
2014
Q4 		$54K Sell
1,834
-4,999
-73% -$123K 0.01% 983
2014
Q3 		$138K Sell
6,833
-15,345
-69% -$296K 0.02% 703
2014
Q2 		$371K Buy
22,178
+21,305
+2,440% +$302K 0.05% 369
2014
Q1 		$13K Buy
+873
New +$13.4K ﹤0.01% 2322
2013
Q4 		– Sell
-3,087
Closed -$53K – 4424
2013
Q3 		$53K Buy
3,087
+2,028
+192% +$30.1K 0.01% 1853
2013
Q2 		$12K Buy
+1,059
New +$12.1K ﹤0.01% 2170

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Tower Research Capital (TRC)'s AMED Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Amedisys (AMED) in Q3 2025, closing a stake of 669 shares — an estimated $65.8K sold.

Tower Research Capital (TRC) first reported a position in AMED in Q2 2013 and held it in 43 quarters. The position peaked at $3.75M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 669 Amedisys shares in Q3 2025, an estimated $65.8K.
  • Tower Research Capital (TRC) first reported a position in Amedisys in Q2 2013 and held it in 43 quarters.
  • Tower Research Capital (TRC)'s Amedisys position peaked at $3.75M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.